207 related articles for article (PubMed ID: 29285650)
1. Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2018 Feb; 59(2):383-394. PubMed ID: 29285650
[TBL] [Abstract][Full Text] [Related]
2. The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Tumour Biol; 2017 Oct; 39(10):1010428317722068. PubMed ID: 28982310
[TBL] [Abstract][Full Text] [Related]
3. Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Endocrinol Invest; 2018 Jun; 41(6):677-689. PubMed ID: 29147952
[TBL] [Abstract][Full Text] [Related]
4. The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms.
Hwang HJ; Chung HS; Jung TW; Ryu JY; Hong HC; Seo JA; Kim SG; Kim NH; Choi KM; Choi DS; Baik SH; Yoo HJ
Mol Cell Endocrinol; 2015 Apr; 405():25-34. PubMed ID: 25661535
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation.
Choi SH; Park S; Oh CJ; Leem J; Park KG; Lee IK
Vascul Pharmacol; 2015 Oct; 73():11-9. PubMed ID: 26187356
[TBL] [Abstract][Full Text] [Related]
6. A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.
Hwang HJ; Jung TW; Kim BH; Hong HC; Seo JA; Kim SG; Kim NH; Choi KM; Choi DS; Baik SH; Yoo HJ
Biochem Pharmacol; 2015 Nov; 98(1):157-66. PubMed ID: 26297911
[TBL] [Abstract][Full Text] [Related]
7. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.
Kim SH; Lee SH; Yim HJ
Arch Pharm Res; 2013 Oct; 36(10):1185-8. PubMed ID: 23771499
[TBL] [Abstract][Full Text] [Related]
8. Evodiamine Suppresses Survival, Proliferation, Migration and Epithelial-Mesenchymal Transition of Thyroid Carcinoma Cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Lee SJ
Anticancer Res; 2018 Nov; 38(11):6339-6352. PubMed ID: 30396956
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl petidase-IV inhibitor (gemigliptin) inhibits tunicamycin-induced endoplasmic reticulum stress, apoptosis and inflammation in H9c2 cardiomyocytes.
Hwang HJ; Jung TW; Ryu JY; Hong HC; Choi HY; Seo JA; Kim SG; Kim NH; Choi KM; Choi DS; Baik SH; Yoo HJ
Mol Cell Endocrinol; 2014 Jul; 392(1-2):1-7. PubMed ID: 24813659
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
Lim S; Han KA; Yu J; Chamnan P; Kim ES; Yoon KH; Kwon S; Moon MK; Lee KW; Kim DJ; Kim M; Wongtanate M; Kim EY; Kim SH; Lee MK;
Diabetes Obes Metab; 2017 Jan; 19(1):87-97. PubMed ID: 27619558
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Shin D; Cho YM; Lee S; Lim KS; Kim JA; Ahn JY; Cho JY; Lee H; Jang IJ; Yu KS
Clin Drug Investig; 2014 Jun; 34(6):383-93. PubMed ID: 24627290
[TBL] [Abstract][Full Text] [Related]
13. Enigma Plays Roles in Survival of Thyroid Carcinoma Cells through PI3K/AKT Signaling and Survivin.
Kim YJ; Hwang HJ; Kang JG; Kim CS; Ihm SH; Choi MG; Lee SJ
Anticancer Res; 2018 Jun; 38(6):3515-3525. PubMed ID: 29848705
[TBL] [Abstract][Full Text] [Related]
14. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo.
Jung E; Kim J; Kim SH; Kim S; Cho MH
Eur J Pharmacol; 2014 Dec; 744():98-102. PubMed ID: 25448307
[TBL] [Abstract][Full Text] [Related]
15. Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.
Seo JB; Choi YK; Woo HI; Jung YA; Lee S; Lee S; Park M; Lee IK; Jung GS; Park KG
Diabetes Metab J; 2019 Dec; 43(6):830-839. PubMed ID: 30877711
[TBL] [Abstract][Full Text] [Related]
16. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
[TBL] [Abstract][Full Text] [Related]
17. Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.
Jin L; Lim SW; Jin J; Chung BH; Yang CW
Transl Res; 2016 Aug; 174():122-39. PubMed ID: 27059001
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells.
Choi SY; Ryu HM; Oh EJ; Choi JY; Cho JH; Kim CD; Kim YL; Park SH
PLoS One; 2017; 12(7):e0180393. PubMed ID: 28686724
[TBL] [Abstract][Full Text] [Related]
19. Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.
Choi SH; Leem J; Lee IK
Mediators Inflamm; 2017; 2017():4139439. PubMed ID: 29317794
[TBL] [Abstract][Full Text] [Related]
20. Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cells.
Esfahanian N; Shakiba Y; Nikbin B; Soraya H; Maleki-Dizaji N; Ghazi-Khansari M; Garjani A
Mol Med Rep; 2012 Apr; 5(4):1068-74. PubMed ID: 22246099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
